Beijing Tiantan Biological Products Corporation (600161.SH) subsidiary plasma station has obtained a blood plasma collection license.
TianTan Biological (600161.SH) announced that its controlling subsidiary, China National Pharmaceutical Group Lanzhou Biological Pharmaceutical Co., Ltd., has received the "Plasma Collection License" issued by the Gansu Provincial Health and Health Committee for its subordinate plasma collection companies: Gaolan Lansheng Plasma Collection Co., Ltd., Yongdeng Lansheng Plasma Collection Co., Ltd., Gangu Lansheng Plasma Collection Co., Ltd., and Jinta Lansheng Plasma Collection Co., Ltd. The above plasma stations have been approved for registration and are permitted to operate. The acquisition of the "Plasma Collection License" by these stations is beneficial for expanding the company's raw plasma collection scale, promoting an increase in plasma collection volume, and has a positive impact on the long-term development of the company.
Beijing Tiantan Biological Products Corporation (600161.SH) issued an announcement stating that its holding subsidiary, China National Pharmaceutical Group Lanzhou Biological Pharmaceutical Co., Ltd., has received a "Plasma Collection License" issued by the Gansu Provincial Health and Health Commission for its subordinate plasma collection companies: Gaolan Lansheng Plasma Collection Co., Ltd., Yongdeng Lansheng Plasma Collection Co., Ltd., Gangu Lansheng Plasma Collection Co., Ltd., and Jinta Lansheng Plasma Collection Co., Ltd. The above plasma stations have been approved and registered, and are authorized to operate. The acquisition of the "Plasma Collection License" by these plasma stations is beneficial for expanding the company's raw plasma collection scale, promoting the growth of plasma collection volume, and has a positive effect on the company's long-term development.
Related Articles
CGN NEW ENERGY (01811) spent approximately HKD 627,800 to repurchase 296,000 shares on September 7.
Anhui Province Natural Gas Development (603689.SH) plans to acquire a 51% stake in for 174 million yuan.
C-MER MEDICAL (03309) announced on September 7 that it invested HK$70,000 to repurchase 80,000 shares.
CGN NEW ENERGY (01811) spent approximately HKD 627,800 to repurchase 296,000 shares on September 7.
Anhui Province Natural Gas Development (603689.SH) plans to acquire a 51% stake in for 174 million yuan.
C-MER MEDICAL (03309) announced on September 7 that it invested HK$70,000 to repurchase 80,000 shares.
RECOMMEND
